Top 5 Drug Type | Count |
---|---|
Small molecule drug | 15 |
Recombinant protein | 1 |
Synthetic peptide vaccine | 1 |
Target |
Mechanism HDAC6 modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism secretin antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EZH2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SCT-5-27 ( secretin ) | Cholangitis, Sclerosing More | Preclinical |
Metalmeta analogue(Sapienza Università di Roma) ( DNMTS ) | Neoplasms More | Preclinical |
Phenylalanine ammonia lyase encapsulated erythrocytes (EryDel) | Phenylketonurias More | Preclinical |
RS6212 ( L-lactate dehydrogenase ) | Neoplasms More | Preclinical |
iDual ( HDAC6 x HDAC8 x KDM1A ) | Lymphoma More | Preclinical |